http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2011130434-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2320-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1135 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K48-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate | 2005-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-01-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2011130434-A |
| titleOfInvention | OLIGORIBONUCLEOTIDES AND WAYS OF THEIR APPLICATION FOR TREATMENT OF ACUTE RENAL FAILURE AND OTHER DISEASES |
| abstract | 1. The compound having the structure 5 '(N) -Z3' (antisense chain) 3'Z '- (N') 5 '(sense chain) where each N and N' means ribonucleotide, which may be modified or unmodified at its residue , and (N) and (N ') means an oligomer in which each consecutive N or N' is connected with the subsequent N or N 'covalent bond; where each of x and y is an integer from 19 to 40; where each of Z and Z 'may be present or absent, but if present, means dTdT and is covalently attached at the 3'-end of the chain in which it is present; where sequence (N) contains relative to p53.2 mRNA. The compound according to claim 1, where the sequence (N) contains one or more antisense sequences shown in tables A, B and C.3. A compound according to claim 2, wherein the covalent bond is a phosphodiester bond. The compound according to claim 3, where x = y, preferably, where x = y = 19.5. The compound according to claim 4, where both Z and Z 'are absent. A compound according to claim 4, wherein one of Z or Z ′ is present. The compound according to claim 5, where all the ribonucleotides are unmodified by their sugar residues. A compound according to claim 5, wherein at least one ribonucleotide is modified according to its sugar residue. The compound of claim 8, wherein the modification of the sugar residue comprises a modification at position 2'.10. The compound according to claim 9, wherein the modification at position 2 ′ results in the formation of a part of a molecule selected from the group from amino, fluoro, methoxy, alkoxy and alkyl groups. The compound of claim 10, wherein said portion of the molecule at position 2 ′ is methoxy (2′-O-methyl). The compound of claim 11, wherein the antisymmetric ribonucleotides are modified in both the antisense and sense chains. The compound of claim 12, wherein the rib |
| priorityDate | 2004-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 88.